British Journal of Cancer - Volume 60, issue 4

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras neque tellus, ornare vel pulvinar luctus, vestibulum malesuada ante. Nullam pellentesque, ipsum vel fermentum tincidunt, velit neque molestie lacus, at iaculis purus mauris in nisl. Nullam vehicula imperdiet auctor. Mauris tempus, leo eget euismod condimentum, erat justo vehicula augue, vitae ornare elit felis nec libero. Etiam et quam sit amet metus dignissim dictum sed vitae purus. Phasellus gravida hendrerit risus vitae euismod. In elementum massa facilisis nulla pulvinar at pharetra leo pellentesque.

Electronic ISSN
1532-1827
Print ISSN
0007-0920

Abstract

Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and tox

Journal: British Journal of Cancer, vol. 60, no. 4, 1989

Abstract

Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indica

Journal: British Journal of Cancer, vol. 60, no. 4, 1989